Hoppa till innehållet

OMXSPI-0,23%

S&P 500+0,12%

FTSE 100-0,22%

DAX-0,18%

NIKKEI-0,34%
Redeye: XVIVO - Stepping up the pace during 2024

Redeye updates our outlook after Q4 2023. XVIVO delivers improved gross margins with a softer organic growth of 12% (CER) and a quarter with higher OPEX. Thoracic disposables recorded sales below expectations, with surprisingly high gross margins at 85% in Q4. The outlook remains positive, and the critical US Heart study has started. We reduce our base case to SEK 425 (450) with a Bull of SEK 850 (900) and a Bear of SEK 95 (105).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

XVIVO - Stepping up the pace during 2024

Source:MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera